
Percent Inhibition of PD-1 binding to PD-L1+ cells by Anti-PD-L1 Antibodies
% Inhibition
100
50
0
-7.5
-7.0
-6.5
-6.0
-5.5
-5.0
-4.5
Log[ug/mL]
Clinical Control
CTI-09
CTI-48
CTI-50
CTI-58

FIGURE 1


A.
huPD-L1
Loading Sample ID: ADI-Z1584; Sample ID: huPDL1;
KD (M): 8.474E-10 - by Conc. (nM)
0.16
0.08
0
nm
0
50
100
150
200
250
Time (sec)
33.3
11.1
3.7
1.24
B.
msPD-L1
Loading Sample ID: ADI-Z1584; Sample ID: msPDL1;
KD (M): 3.411E-12 - by Conc. (nM)
0.16
0.08
0
nm
0
50
100
150
200
250
Time (sec)
33.3
11.1
3.7
1.24

FIGURE 2



FIGURE 2, CONT'D


SUDHL-1 lymphoma cell line ADCC - Fresh PBMCs PDL1
Percent Cytotoxicity
25%
20%
15%
10%
5%
0%
IgG1-Fc 3ug/mL
CTI-48 3ug/mL
CTI-48 1ug/mL
Donor 0263
IgG1-Fc 3ug/mL
CTI-48 3ug/mL
CTI-48 1ug/mL
Donor 0265

FIGURE 3


PD-L1 immunoblockade reporter assay
Fold induction
8
6
4
2
0
-9
-8
-7
-6
-5
-4
log [g/mL]
Clinical Control mAb
CTI-48
CTI-49

FIGURE 4



	Clinical control mAb	CTI-048	Negative control mAb
IC50	0.4909	0.1941	~ 0.0

FIGURE 5


*
*
10
8
6
4
2
0
IFN-gamma, fold change over vehicle control
Negative control IgG1
Clinical control mAb
CTI-48
Antibody, 10 μg/ml

FIGURE 6